tetragenex pharmaceuticals i
(TTRXQ:OTC US)
tetragenex pharmaceuticals i (TTRXQ) Snapshot
|
Open
$0.01
|
Previous Close
$0.01
|
|
|
Day High
$0.01
|
Day Low
$0.01
|
|
|
52 Week High
05/7/13 - $0.01
|
52 Week Low
11/12/12 - $0.0001
|
|
|
Market Cap
188.0K
|
Average Volume 10 Days
0.0
|
|
|
EPS TTM
--
|
Shares Outstanding
18.8M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
tetragenex pharmaceuticals i (TTRXQ) Related Businessweek News
No Related Businessweek News Foundtetragenex pharmaceuticals i (TTRXQ) Details
Tetragenex Pharmaceuticals, Inc., a biotechnology company, engages in the development and commercialization of proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The company’s principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. It also develops other central nervous systems active peptides, as second-generation medications for the treatment of depression, anxiety, and other psychiatric disorders. The company was founded in 1989 and is headquartered in Syosset, New York.
| Recently Viewed | |||
| TTRXQ:US | $0.01 USD | 0.00 |  |
| Company | Last | Change | |
| No competitor information is available for TTRXQ. | |||
| View Industry Companies | |||
Industry Analysis
TTRXQ
Industry Average
| Valuation | TTRXQ | Industry Range |
| Price/Earnings | 0.1x |
|
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | 0.2x |
|
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact TETRAGENEX PHARMACEUTICALS I, please visit www.tetragenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
